Edwards Lifesciences: Favorable Data From Early TAVR Trial Paves Way for Long-Term Growth

Edwards shared impressively favorable clinical data from the Early transcatheter aortic replacement valve, or TAVR, trial that demonstrated positive outcomes for severe aortic stenosis, or AS, patients even when they were asymptomatic.